The identification of MET amplification in the patient’s tumor, a well-established mechanism of resistance to anti-EGFR therapy (Engelman et al., 2007), led to the prescription of a combination of erlotinib and the MET inhibitor crizotinib. This evidence concerns the gene EGFR and neoplasm.